---
schema_version: "secwatch.filing_event.v1"
accession: "0000879407-26-000058"
form_type: "8-K"
ticker: "ARWR"
cik: "0000879407"
company_name: "ARROWHEAD PHARMACEUTICALS, INC."
filed_at: "2026-08-04T20:03:02+00:00"
generated_at: "2026-08-04T20:04:53.967290+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Arrowhead Q3 revenue $75.3M; plozasiran Phase 3 hits endpoints; Madrigal license deal

## Summary
- Revenue $75.3M (up 171% YoY); net loss $194.3M ($1.36 diluted EPS) vs $175.2M ($1.26) prior year.
- Plozasiran Phase 3 SHASTA-3/4: 79% and 81% median triglyceride reductions; 78% reduction in acute pancreatitis events.
- Acquired FDA priority review voucher for plozasiran sNDA in sHTG, expected before end of 2026.
- Exclusive license to Madrigal for ARO-PNPLA3: $25M upfront, up to $975M milestones, tiered royalties.
- REDEMPLO prescriptions roughly doubled in Q3; >400 prescribers; EU and Australia marketing authorizations.

## SEC filing metadata
- accession: 0000879407-26-000058
- form_type: 8-K
- ticker: ARWR
- cik: 0000879407
- company_name: ARROWHEAD PHARMACEUTICALS, INC.
- filed_at: 2026-08-04T20:03:02+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/879407/000087940726000058/0000879407-26-000058-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/879407/000087940726000058/arwr-20260804.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000879407-26-000058
- JSON: https://secwatch.observer/filing/0000879407-26-000058.json
- Plain text: https://secwatch.observer/filing/0000879407-26-000058.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.